Inventiva’s Innovative ATM Program Introduction
Inventiva, a clinical-stage biopharmaceutical company, has embarked on an exciting journey by introducing a new At-The-Market (ATM) program. This initiative, as part of their broader strategy, aims to fund the development of crucial oral therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). The company has filed a shelf registration statement, paving the way for potential capital influx to support its innovative projects.
Funding Volumes and Usage
Through this ATM program, Inventiva is aiming to raise up to $100 million in gross sales proceeds, with the flexibility to offer its ordinary shares in the form of American Depositary Shares (ADS). This creative financing option will allow the company to sell shares at market prices, giving them the advantage of agile capital raising based on market demand. Inventiva plans to utilize the net proceeds to finance research and development activities, specifically for lanifibranor, as well as for working capital and corporate purposes.
Investing and Selling Mechanisms
The ATM program is structured to ensure compliance with regulatory guidelines. Shares issued under this program will represent less than 30% of the ordinary shares already trading, maintaining a careful approach to dilutive effects on current shareholders. Eligible investors, which include various individuals and institutions familiar with the pharmaceutical and biotech sectors, will have the opportunity to engage in this capital expansion.
Strategic Partnerships and Sales Processes
Piper Sandler & Co. has been appointed as the sales agent for this initiative, tasked with executing sales effectively while adhering to standard trading practices. This partnership highlights Inventiva’s commitment to strategic collaborations that bolster its operational capacity. Sales prices will reflect the current market's behavior, requiring transparency and fairness in all transactions.
Results Reporting and Transparency
Inventiva is committed to fostering investor relations through transparency. The company will provide updates on its use of the ATM program during quarterly result releases, ensuring that stakeholders are informed about the outcomes and terms of each issuance conducted under this program. This proactive communication strategy underscores Inventiva's dedication to maintaining trust with its investors.
Future Prospects for Inventiva
The road ahead looks promising for Inventiva as it advances its clinical trials for lanifibranor, a pioneering therapy for MASH. With this ATM program, the company aims not only to improve its financial standing but also to expedite the development of therapies that significantly impact patient health. As the clinical trial progresses, the funds generated through the ATM program could help expedite processes and enhance research efforts.
Admitted Trading and Market Position
The ordinary shares underlying the ADS will be admitted to trading in Paris, with the ADS trading on Nasdaq. This dual market presence positions Inventiva strategically to access diverse investor bases and maintain a competitive edge in the biopharmaceutical landscape. As the company continues to innovate, the support from investors will play a critical role in its growth and success.
Frequently Asked Questions
What is Inventiva's ATM program?
The ATM program allows Inventiva to raise capital by selling shares at market prices, funding their research and development efforts.
How much does Inventiva aim to raise through this program?
Inventiva is targeting gross sales proceeds of up to $100 million through the ATM program.
Who can invest in the ATM program?
The program is open to eligible investors, including individuals and institutions that invest in pharmaceutical and biotechnology sectors.
What are the purposes of the proceeds from the ATM program?
The proceeds will be used for research and development of lanifibranor, working capital, and other corporate purposes.
What is lanifibranor?
Lanifibranor is Inventiva's novel therapy currently in Phase 3 trials targeting metabolic dysfunction-associated steatohepatitis (MASH).
